AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03588741
Drug: Turoctocog alfa
RxNorm normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month.
Trial: NCT01836757
Drug: MethylSulfonylMethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Trial: NCT01417767
Drug: 5-aza-deoxycytidine
RxNorm normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
Trial: NCT01245608
Drug: Polypill
RxNorm normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
Trial: NCT02423694
Drug: escitalopram oxalate tablets
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
Trial: NCT00473174
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing on awakening versus bedtime
Trial: NCT02100826
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01374087
Drug: Triptorelin 22.5 mg
RxNorm normalized name: triptorelin 22.5 MG
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
Trial: NCT00561379
Drug: CHOP+RITUXIMAB
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CHOP-14- Rituximab x 8 courses
Trial: NCT00561379
Drug: CEEP-RITUXIMAB
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High dose chemotherapy with rituximab including autologous stem cell support.
Trial: NCT00380146
Drug: sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05594186
Drug: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
Trial: NCT02427932
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
Trial: NCT01146197
Drug: TREATMENT
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
Trial: NCT00420511
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 100 mg once a day
Trial: NCT00442702
Drug: Mircera
RxNorm normalized name: Mircera
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
Trial: NCT00442702
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
Trial: NCT02078869
Drug: Progesterone in oil
RxNorm normalized name: Progesterone 50 MG/1 ML Intramuscular Oil [PROGESTERONE IN OIL]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily administration of 50 mg of IM Progesterone
Trial: NCT02078869
Drug: vaginal progesterone suppositories
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal Promterium 200 mg , 3 times a day
Trial: NCT00420511
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1000 mg twice a day (bid) by mouth (po)
Trial: NCT01668654
Drug: retigabine/ezogabine
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
Trial: NCT00454779
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy arm
Trial: NCT00454779
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: experimental arm
Trial: NCT00454779
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy arm
Trial: NCT00454779
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental arm
Trial: NCT00454779
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental arm
Trial: NCT00004419
Drug: insulin-like growth factor I
RxNorm normalized name: Insulin-like growth factor I
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03898011
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
Trial: NCT03898011
Drug: Lamictal
RxNorm normalized name: Lamictal
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
Trial: NCT03182855
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
Trial: NCT03182855
Drug: Cangrelor Tetrasodium
RxNorm normalized name: Cangrelor tetrasodium
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
Trial: NCT02310269
Drug: Pasireotide
RxNorm normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02499237
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
Trial: NCT03487133
Drug: bortezomib/dexamethasone
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none
Trial: NCT02137408
Drug: Docosahexaenoic acid 1000 mg
RxNorm normalized name: docosahexaenoic acid 1000 MG
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
Trial: NCT02908100
Drug: GDC-0853
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
Trial: NCT03388827
Drug: Laminaria plus Misoprostol
RxNorm normalized name: Laminaria digitata preparation
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
Trial: NCT00925275
Drug: I-131-CLR1404
RxNorm normalized name: I-131-CLR1404
DrugBank: Iopofosine I-131 (DB15244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
Trial: NCT02866747
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03840967
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
Trial: NCT01765400
Drug: Prasugrel 10 mg daily x 2 weeks
RxNorm normalized name: prasugrel 10 MG
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01765400
Drug: Clopidogrel 75 mg daily x 2 weeks
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03575598
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
Trial: NCT02552225
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
Trial: NCT01085903
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg once daily with morning meal for three days administered only to stroke patients
Trial: NCT02296099
Drug: liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
Trial: NCT02971839
Drug: VX-561
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02971839
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02625428
Drug: Optison
RxNorm normalized name: Optison
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00375232
Drug: Administration of montelukast or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02085863
Drug: laquinimod
RxNorm normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Trial: NCT03514576
Drug: Pasireotide 0.3 MG/ML
RxNorm normalized name: pasireotide 0.3 MG/ML
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT01104467
Drug: Desmoteplase
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
Trial: NCT01104467
Drug: Desmoteplase
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 bolus injection of desmoteplase 90 µg/kg (IV)
Trial: NCT01467492
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT00371124
Drug: Atropine Eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00865748
Drug: Metformin HCl 500 mg tablets, single dose
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Trial: NCT04388826
Drug: Veru-111
RxNorm normalized name: Veru-111
DrugBank: Veru-111 (DB16462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory Distress Syndrome, Adult
Trial: NCT01467492
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT00443456
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
Trial: NCT01734044
Drug: recombinant human thrombopoietin (rhTPO); dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
Trial: NCT01734044
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Trial: NCT02458235
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
Trial: NCT00423059
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01358734
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
Trial: NCT01358734
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
Trial: NCT03274778
Drug: Ruxolitinib 20 MG
RxNorm normalized name: ruxolitinib 20 MG
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT02169596
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood tests taken for flow cytometry
Trial: NCT00490711
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00490711
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00490711
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00890500
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2/day IV x 6 days
Trial: NCT01404715
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
Trial: NCT00890500
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2/day IV x 1 day
Trial: NCT00890500
Drug: Antithymocyte Globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg/day x 4 days
Trial: NCT00890500
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GVHD Prophylaxis: Target range 3-12 ng/ml
Trial: NCT00890500
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GVHD Prophylaxis: Target range 5-10 ng/ml
Trial: NCT00687076
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 10 mg of Ezetimibe
Trial: NCT00687076
Drug: Niaspan
RxNorm normalized name: Niaspan
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1500 mg of Niaspan
Trial: NCT00687076
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose of 325 mg of aspirin
Trial: NCT00687076
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
Trial: NCT00687076
Drug: Placebo Niaspan
RxNorm normalized name: Niaspan
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1500 mg of placebo Niaspan
Trial: NCT00687076
Drug: Placebo Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 10 mg of placebo Ezetimibe
Trial: NCT00822094
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01066845
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prescribed in accordance with usual clinical practice
Trial: NCT02644551
Drug: Penlac
RxNorm normalized name: Penlac Nail Lacquer
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03610048
Drug: ALKS 5461
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: samidorphan + buprenorphine administered sublingually
Trial: NCT00647647
Drug: Terbinafine Hydrochloride Tablets 250 mg
RxNorm normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg, single dose fasting
Trial: NCT02884453
Drug: ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
Trial: NCT02477748
Drug: MDX
RxNorm normalized name: MDX 11
DrugBank: pM-81 (DB17432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
Trial: NCT01404715
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of 600 mg of imatinib
Trial: NCT01705392
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg q3w
Trial: NCT01705392
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg x 1
Trial: NCT01705392
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg x 1
Trial: NCT01705392
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dacarbazine 1000 mg/m2 q3w
Trial: NCT00855361
Drug: Rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
Trial: NCT04987372
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The use of multimodal painkillers pre, per and postoperative